We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
Read MoreHide Full Article
Shares of Vaxart, Inc. (VXRT - Free Report) have risen sharply in the year so far. The stock has skyrocketed 4359.4% against the industry’s decrease of 4.7%.
The company has been in the spotlight this year following its efforts to develop an oral vaccine against the deadly coronavirus disease (COVID-19).
Last month, Vaxart’s oral COVID-19 vaccine candidate was selected for investigation in a non-human primate (NHP) challenge study. The new study will be organized and funded by Operation Warp Speed (OWS), which is a new national program, to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
Following this development, the company’s candidate became the first oral COVID-19 vaccine, which will be tested by OWS in non-human primates. The study is designed to demonstrate the efficacy of the oral COVID-19 vaccine candidate.
In April this year, the company announced favorable data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19. Several vaccine candidates were able to generate immune responses after a single dose in all the animals under the studies was tested.
Following the positive data, in May, Vaxart selected its lead oral COVID-19 vaccine candidate from multiple vaccine candidates, which were evaluated in its preclinical studies. The company plans to start a phase I study on the oral tablet vaccine candidate in the second half of this year. Notably, the candidate was developed leveraging the company’s proprietary oral vaccine platform, VAAST.
Meanwhile, Vaxart signed a contract with Emergent BioSolutions (EBS - Free Report) and Kindred Biosciences, to produce bulk vaccine under cGMP for its clinical studies. The vaccine tablets will be manufactured at Vaxart.
We note that Vaxart’s portfolio is currently devoid of any approved product. As a result, it is yet to generate any revenues from product sales. If the company is able to successfully develop and commercialize the oral COVID-19 vaccine, it will be a huge boost to its stock in the days ahead. However, competition remains stiff as small biotechs, namely Moderna (MRNA - Free Report) , Novavax (NVAX - Free Report) and some big pharma companies as well are actively engaged in developing a vaccine to fight the deadly COVID-19 pandemic.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Vaxart's Soars YTD on Robust Coronavirus Vaccine Progress
Shares of Vaxart, Inc. (VXRT - Free Report) have risen sharply in the year so far. The stock has skyrocketed 4359.4% against the industry’s decrease of 4.7%.
The company has been in the spotlight this year following its efforts to develop an oral vaccine against the deadly coronavirus disease (COVID-19).
Last month, Vaxart’s oral COVID-19 vaccine candidate was selected for investigation in a non-human primate (NHP) challenge study. The new study will be organized and funded by Operation Warp Speed (OWS), which is a new national program, to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
Following this development, the company’s candidate became the first oral COVID-19 vaccine, which will be tested by OWS in non-human primates. The study is designed to demonstrate the efficacy of the oral COVID-19 vaccine candidate.
In April this year, the company announced favorable data from pre-clinical studies on its oral vaccine candidates against SARS CoV-2, the virus that causes COVID-19. Several vaccine candidates were able to generate immune responses after a single dose in all the animals under the studies was tested.
Following the positive data, in May, Vaxart selected its lead oral COVID-19 vaccine candidate from multiple vaccine candidates, which were evaluated in its preclinical studies. The company plans to start a phase I study on the oral tablet vaccine candidate in the second half of this year. Notably, the candidate was developed leveraging the company’s proprietary oral vaccine platform, VAAST.
Meanwhile, Vaxart signed a contract with Emergent BioSolutions (EBS - Free Report) and Kindred Biosciences, to produce bulk vaccine under cGMP for its clinical studies. The vaccine tablets will be manufactured at Vaxart.
We note that Vaxart’s portfolio is currently devoid of any approved product. As a result, it is yet to generate any revenues from product sales. If the company is able to successfully develop and commercialize the oral COVID-19 vaccine, it will be a huge boost to its stock in the days ahead. However, competition remains stiff as small biotechs, namely Moderna (MRNA - Free Report) , Novavax (NVAX - Free Report) and some big pharma companies as well are actively engaged in developing a vaccine to fight the deadly COVID-19 pandemic.
VAXART, INC. Price
VAXART, INC. price | VAXART, INC. Quote
Zacks Rank
Vaxart currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>